RCKT Straddle Strategy

RCKT (Rocket Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.

RCKT (Rocket Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $354.9M, a beta of 0.47 versus the broader market, a 52-week range of 2.4-5.45, average daily share volume of 3.1M, a public-listing history dating back to 2015, approximately 299 full-time employees. These structural characteristics shape how RCKT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.47 indicates RCKT has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a straddle on RCKT?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

Current RCKT snapshot

As of June 30, 2026, spot at $3.40, ATM IV 133.80%, IV rank 26.37%, expected move 38.36%. The straddle on RCKT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this straddle structure on RCKT specifically: RCKT IV at 133.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a RCKT straddle, with a market-implied 1-standard-deviation move of approximately 38.36% (roughly $1.30 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RCKT expiries trade a higher absolute premium for lower per-day decay. Position sizing on RCKT should anchor to the underlying notional of $3.40 per share and to the trader's directional view on RCKT stock.

RCKT straddle setup

The RCKT straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RCKT near $3.40, the first option leg uses a $3.40 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RCKT chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RCKT shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$3.40	N/A
Buy 1	Put	$3.40	N/A

RCKT straddle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

RCKT straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on RCKT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use straddle on RCKT

Straddles on RCKT are pure-volatility plays that profit from large moves in either direction; traders typically buy RCKT straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

RCKT thesis for this straddle

The market-implied 1-standard-deviation range for RCKT extends from approximately $2.10 on the downside to $4.70 on the upside. A RCKT long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current RCKT IV rank near 26.37% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on RCKT at 133.80%. As a Healthcare name, RCKT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RCKT-specific events.

RCKT straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RCKT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RCKT alongside the broader basket even when RCKT-specific fundamentals are unchanged. Always rebuild the position from current RCKT chain quotes before placing a trade.

Frequently asked questions

What is a straddle on RCKT?: A straddle on RCKT is the straddle strategy applied to RCKT (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With RCKT stock trading near $3.40, the strikes shown on this page are snapped to the nearest listed RCKT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are RCKT straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the RCKT straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 133.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a RCKT straddle?: The breakeven for the RCKT straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RCKT market-implied 1-standard-deviation expected move is approximately 38.36%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on RCKT?: Straddles on RCKT are pure-volatility plays that profit from large moves in either direction; traders typically buy RCKT straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current RCKT implied volatility affect this straddle?: RCKT ATM IV is at 133.80% with IV rank near 26.37%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.